CVRx, Inc. Reports Revenue Growth in Q1 2025

Cvrx, Inc. ( (CVRX) ) has released its Q1 earnings. Here is a breakdown of the information Cvrx, Inc. presented to its investors.

CVRx, Inc. is a commercial-stage medical device company specializing in innovative neuromodulation solutions for cardiovascular diseases, with its flagship product, Barostim, aimed at treating heart failure. In the first quarter of 2025, CVRx reported a 15% increase in total revenue, reaching $12.3 million, driven primarily by growth in the U.S. heart failure market. The company expanded its active implanting centers in the U.S. to 227, reflecting a 19% increase from the previous year, and presented significant real-world evidence of Barostim’s effectiveness in reducing hospital visits at a major conference. Key financial metrics showed a gross profit increase to $10.3 million, although the net loss narrowed to $13.8 million from $22.2 million in the same quarter of the previous year. The reduction in losses was attributed to decreased R&D and SG&A expenses, despite increased interest expenses. Looking ahead, CVRx expects continued revenue growth and aims to capitalize on its expanded sales force and clinical evidence to enhance Barostim’s market penetration.